APP and Alzheimer disease: If miR-455-3p is capable of reducing full-length APP and its toxicities in mice, it is important to cross miR-455-3p TG and KO with mouse models of AD, particularly mice with intact 3’ UTR, say newly developed humanized Ab-KI mice.